Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170)

AIDS

Volumn 26, Issue 11, 2012, Pages 1452-

  McLinden, Robert ^a   Paris, Robert ^b   Polonis, Victoria ^c   Close, Nicole ^d   Su, Zhaohui ^e   Shikuma, Cecilia ^f   Margolis, David ^g   Kim, Jerome ^h  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c Military HIV Research Program   (United States)

^d EmpiriStat Inc   (United States)

^e Outcome Sciences Inc   (United States)

^f UNIVERSITY OF HAWAII   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84863697591     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283550b8e     Document Type: Letter

References (10)

1. Nicastri E, Dori L, Buonomini AR, Tommasi C, De Nardo P, Bellagamba R, et al. HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy. AIDS 2012; 26:1451-1452.
2. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655. (Pubitemid 24183063)
3. Pellegrin I, Legrand E, Neau D, Bonot P, Masquelier B, Pellegrin JL, et al. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:438-447. (Pubitemid 26135080)
4. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997; 71:3734-3741. (Pubitemid 27172386)
5. Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, Hanson CV. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1994; 7:211-219.
6. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312. (Pubitemid 36378357)
7. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson EE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by pasive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210. (Pubitemid 30082367)
8. Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J. Neutralizing antibodies are positively associated with CD4R T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998; 12:1591-1600. (Pubitemid 28418328)
9. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15:866-870.
10. Kim JH, Mascola JR, Ratto-Kim S, VanCott TC, Loomis-Price L, Cox JH, et al. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res Hum Retroviruses 2001; 17:1021-1034. (Pubitemid 32881321)